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‘Omics’a b s t r a c t
Vaccines are one of the most effective interventions to improve public health, however, the generation of
highly effective vaccines for many diseases has remained difficult. Three chronic diseases that character-
ise these difficulties include malaria, tuberculosis and HIV, and they alone account for half of the global
infectious disease burden. The whole organism vaccine approach pioneered by Jenner in 1796 and refined
by Pasteur in 1857 with the ‘‘isolate, inactivate and inject’’ paradigm has proved highly successful for
many viral and bacterial pathogens causing acute disease but has failed with respect to malaria,
tuberculosis and HIV as well as many other diseases. A significant advance of the past decade has been
the elucidation of the genomes, proteomes and transcriptomes of many pathogens. This information pro-
vides the foundation for new 21st Century approaches to identify target antigens for the development of
vaccines, drugs and diagnostic tests. Innovative genome-based vaccine strategies have shown potential
for a number of challenging pathogens, including malaria. We advocate that genome-based rational
vaccine design will overcome the problem of poorly immunogenic, poorly protective vaccines that has
plagued vaccine developers for many years.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Vaccines – the global need
The term ‘vaccine’ is derived from Variolae vaccinae, literally
smallpox of the cow, and was coined by Edward Jenner in 1798
in an article describing the protective effect of cowpox against
smallpox (Jenner, 1798; Cohen et al., 1961; Baxby, 1999; Tuells,
2012). Since then, vaccines have been established as one of the
most efficient and cost-effective interventions for the control and
eradication of disease, and the prevention of morbidity and mortal-
ity worldwide. No other modality has had such a major effect on
reducing mortality and improving public health, except for water
sanitation (World Health Organization, 2006). Moreover, vaccinol-
ogy is the only science that has eradicated an infectious disease
(Andre, 2003), with the landmark achievement in 1977 of the erad-
ication of smallpox (Fenner, 1982), a disease that plagued human-
kind and shaped our history since earliest civilisation (Fenner et al.,
1988). It is anticipated that poliomyelitis will soon be eradicated,
although some challenges remain (Pallansch and Sandhu, 2006).
Infectious diseases are responsible for one-third of all deaths
worldwide, killing at least 15 million people each year (http://www.who.int/healthinfo/global_burden_disease/gbd/en/). They
are clearly established as the leading cause of death of children
globally and are responsible for 64–68% of deaths in children under
5 years of age, approximately 5 million children each year (Black
et al., 2010; Liu et al., 2012). It is estimated that at least 3 million
deaths per year are prevented by licensed vaccines currently in use
(World Health Organization, 2007, 2009). Mass smallpox vaccina-
tion of children became compulsory in the United Kingdom (UK)
in 1853 and vaccines are now available for most viral and bacterial
diseases common in children including diphtheria (1923), whoop-
ing cough (1926), tetanus (1937), influenza (1942), pertussis
(1949), polio (1958 and 1961), measles (1963), mumps (1967),
rubella (1969), bacterial meningitis (1974), pneumonia (1983),
varicella (1995) and rotavirus (1998) (http://www.who.int/immu-
nization/policy/position_papers/en/). However, many of these
existing vaccines are underutilised and theWorld Health Organiza-
tion has estimated that 2.5 million children under the age of
5 years die from vaccine-preventable diseases each year, more
than 6800 child deaths every day (World Health Organization,
2007). There are also many serious pathogens for which effective
vaccines are not yet available including hepatitis C virus (HCV),
human immunodeficiency virus (HIV), Dengue, respiratory syncy-
tial virus (RSV) and cytomegalovirus (CMV); bacteria (e.g. Myco-
bacterium tuberculosis (TB), Group A streptococcus (GAS), Group B
902 D.L. Doolan et al. / International Journal for Parasitology 44 (2014) 901–913Streptococcus (GBS), Staphylococcus aureus, Meningococcus Group B
(MenB), Shigella, pathogenic Escherichia coli); and parasites (e.g.
Plasmodium, Leishmania, Schistosoma, Trypanosoma) and these are
estimated to claim in excess of 3 million more lives each year
(World Health Organization, 2005, 2007).
It is noteworthy that despite the demonstrated success of vac-
cines in preventing illness caused by viral and bacterial pathogens,
there are not yet any licensed vaccines for parasitic infections of
humans or for any chronic infections by complex pathogens
(World Health Organization, 2006; Moorthy and Kieny, 2010).
The pathogens causing these diseases have adapted to long-term
coexistence with the human immune system and have evolved
sophisticated immune evasion strategies. Many express hundreds
or thousands of potential antigenic targets, often in distinct phases
of their life cycles, so it is perhaps not surprising that vaccine
efforts to develop vaccines based on only a limited number of anti-
gens, often selected on an ad hoc basis and without knowledge of
the antigenic repertoire of the organisms, have not been successful.
Moreover, all currently licensed vaccines for infectious diseases
are prophylactic, preventing the effects of a future infection by the
target pathogen, and there are no licensed therapeutic vaccines for
any chronic or acute infectious disease. The only therapeutic vac-
cine approved by the United States Food and Drug Administration
(US FDA) is for a certain type of metastatic prostate cancer
(Provenge, DendreonCorp, USA; approved in 2010). Prophylactic
vaccines have been developed to prevent human papilloma virus
(HPV) and hepatitis B virus (HBV) which cause chronic infections
and in some cases cancer (Plotkin, 2008; Levine and Esparza,
2009). However, effective vaccines against the three pathogens
responsible for more than half of the global burden of infectious
diseases (malaria, HIV, TB) (World Health Organization, 2006) will
need to be therapeutic, given the chronicity of these infections in
endemic regions.2. History of vaccines
The field of vaccinology originated on 14 May 1796 when
Edward Jenner inoculated an 8 year old boy named James Phipps
with vaccinia virus contained in pus from lesions on the hand of
a milkmaid with cowpox and showed that Phipps did not become
infected with smallpox when subsequently variolated (inoculated,
or in today’s parlance – challenged, with smallpox). Jenner’s sem-
inal study predated formal evidence for the germ theory of disease
(microbial origin) obtained by Louis Pasteur in 1857 and Robert
Koch in 1876 (D’Argenio and Wilson, 2010) which provided the
foundation of empirical vaccine development. A century after Jen-
ner’s observation, proof-of-concept was established with the
development by Louis Pasteur of an attenuated vaccine for chicken
cholera in 1879, an anthrax vaccine in 1881, and a rabies vaccine in
1885 http://www.historyofvaccines.org).
These and subsequent ‘‘first generation’’ vaccines (e.g. Bacillus
Calmette Guerin (BCG)) consisted of live-attenuated pathogens
(typhoid, pertussis, measles, mumps, rubella) or inactivated killed
pathogens (polio, rabies, cholera, hepatitis A, bubonic plague) and
were developed according to the classical ‘‘isolation, inactivation
and injection of disease-causing pathogen’’ approach to vaccine
development established by Pasteur, and using Koch’s postulates
as a general guide.
In the second half of the 20th Century, significant advances in
many fields including cell culture (enabling the growth of viruses
in vitro), polysaccharide chemistry, recombinant DNA technology
and immunology, allowed the development of ‘‘second generation’’
vaccines which comprised purified pathogen components such as
protein antigens or polysaccharides (e.g. polio, measles, mumps,
rubella, chickenpox, tetanus, diphtheria, anthrax, influenza, hepatitisA, hepatitis B, rotavirus, influenza, pneumonia and human papilloma-
virus (Hilleman, 1999; Finco and Rappuoli, 2014; Rhee, 2014).
Maurice Hilleman is widely recognised as a pioneer and the most
prolific developer of vaccines in this period, developing more than
40 vaccines (Hilleman, 1999; http://www.historyofvaccines.org).
It was in this era that Jonas Salk, who developed the first (inac-
tivated) vaccine against polio, defined vaccinology as ‘‘the applica-
tion of the basic requirements for effective immunisation’’ which
include (i) stimulation with a sufficient quantity of antigen, (ii)
use of a suitably specific antigen, and (iii) the induction of an
appropriate immune response for the prevention of the pathologi-
cal consequences of infection; also noting that vaccinology
‘‘requires an understanding of the etiologic agents, the pathogenic
mechanisms, and the epidemiology of the individual diseases’’
(Salk and Salk, 1977). The majority of currently-licensed vaccines
consist of either killed (inactivated) or live attenuated pathogens,
or pathogen-related biomolecules including toxoids or polysaccha-
rides (Grimm and Ackerman, 2013; U.S. Food and Drug
Administration, 2014). It is notable that most currently licensed
vaccines target pathogens with a relatively low degree of antigen
variability and work mainly by eliciting functional antibodies (De
Gregorio and Rappuoli, 2012).
For many significant pathogens, the generation of broadly pro-
tective vaccines has remained elusive. Such pathogens often pres-
ent technical obstacles to the vaccinologist that include their
inability to be cultured in vitro (e.g.Mycobacterium leper, papilloma
virus type), have antigenic hypervariability (e.g. serogroup B men-
ingococcus, HIV, HCV), or whose life cycles have an intracellular
phase that puts them out of the reach of antibodies and therefore
require a cellular immune response - controlled predominantly
by T cells (e.g. malaria, tuberculosis); furthermore, traditional
approaches to vaccine design and development do not allow the
rapid development of new vaccines for pandemic agents (Finco
and Rappuoli, 2014). Most second generation vaccines do not tar-
get these types of pathogens or elicit the correct types of responses
and we have reached a point where most of the low-hanging fruit
has been taken. These challenges are significant and explain why
we have reached the end of the age of second generation vaccine
development.
Advances in genomics and other ‘‘omics’’ over the past two dec-
ades have given rise to a ‘‘third generation’’ of vaccines (e.g. Men-
ingococcus group B, group A streptococcus, group B streptococcus,
S. aureus, E. coli, Clostridium difficile) based on technologies such as
reverse vaccinology pioneered by Rappuoli (2000), structural biol-
ogy and synthetic vaccines (Delany et al., 2014; Finco and
Rappuoli, 2014). This activity has resulted in vaccines that protect
against an increased range of vaccine-preventable diseases, that
are multivalent and target different serotypes, or highly purified
vaccines with an improved safety profile, and replace the more
reactogenic whole cell vaccines (Rappuoli et al., 2011). These
advances, combined with knowledge gained from successes with
vaccine development against acute diseases in the 20th Century,
provide the foundation for the development of vaccines that have
thus far proved elusive, including those that are therapeutic (for
chronic diseases), require cellular immunity for protection, for
pregnant women and elderly or immunocompromised people, or
for new indications such as autoimmune disease and cancer
(Poland and Barrett, 2009; Rappuoli et al., 2011). They also enable
more efficient pathways for vaccine development and new tech-
nologies for assessment of vaccine safety, which are especially per-
tinent given increased public scrutiny of adverse events associated
with vaccination and stringent regulatory requirements for vaccine
approval (Rappuoli et al., 2011).
On May 8, 1980, the World Health Assembly certified the world
free of naturally occurring smallpox, representing a landmark
achievement in the history of vaccinology (Fenner, 1982). The
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launched at the World Economic Forum on 31 January, 2000 with
the involvement of the major players in global immunisation,
including representatives and leaders from key United Nations
(UN) agencies, bilateral aid agencies, the pharmaceutical industry,
major philanthropic foundations and government bodies, all part-
nering with the aim to deliver vaccines to millions of the world’s
poorest children and boost immunisation coverage (http://
www.gavialliance.org/). A decade later, on 29 January 2010, Bill
and Melinda Gates issued a challenge to participants at the World
Economic Forum’s annual meeting to make this the ‘‘Decade of
Vaccines’’ with a commitment of $10 billion over the next 10 years
to help research, develop and deliver vaccines for the world’s poor-
est countries, with a specific goal to prevent the deaths of approx-
imately 8 million children under the age of 5 years from 2010 to
2019 (http://www.gatesfoundation.org/Media-Center/Press-
Releases/2010/01/Bill-and-Melinda-Gates-Pledge-$10-Billion-in-
Call-for-Decade-of-Vaccines). In December 2010, stakeholders
from the global health community, including the World Health
Organization (WHO), the United Nations Children’s Fund (UNICEF),
the US National Institute of Allergy and Infectious Diseases (NIAID)
and the Bill & Melinda Gates Foundation, formally launched the
Decade of Vaccines Collaboration to generate a Global Vaccine
Action Plan (GVAP) 2011–2020 (World Health Organization,
2013). Following extensive consultation, the GVAP was endorsed
by the 194 Member States of the World Health Organization
Assembly on 11 May 2012 to achieve the Decade of Vaccines vision
by delivering universal access to immunisation and preventing
millions of deaths by 2020 and beyond. The GVAP outlines six stra-
tegic objectives to strengthen routine immunisation, and develop
and introduce new and improved vaccines and vaccine technolo-
gies (Keith et al., 2013).3. Empirical to rational vaccine development
Historically, vaccine development has been based on empirical
trial-and-error approaches designed to mimic, by vaccination, the
immunity induced by natural infection, which originated in the
late 17th Century with Jenner. With this classical ‘‘isolate, inacti-
vate and inject’’ approach, protection against a wide range of bac-
terial and viral pathogens (but not parasitic pathogens of humans)
has been achieved, and whole-organism vaccines still represent a
large proportion of the vaccines licensed today.
There are both advantages and disadvantages associated with
whole-organism vaccines (Zepp, 2010; Rappuoli et al., 2011;
Grimm and Ackerman, 2013). A major advantage is that they do
not require prior knowledge of immune responses associated
with protection, or of the pathogen genome or proteome.
Moreover, they typically induce sustained protective immune
responses without the requirement for adjuvant. Importantly,
whole-organism vaccines provide an extensive repertoire of
pathogen-derived B cell and T cell epitopes for recognition by
the immune system of the vaccine in the context of multiple
genetic backgrounds found in heterogeneous human populations,
although only a fraction of these epitopes may be important tar-
gets of protective immunity. In contrast, highly purified antigens
likely present only a limited number of epitopes and therefore
may not be recognised by all individuals (immunological
non-responsiveness).
Despite these advantages, whole-organism killed, inactivated or
live attenuated vaccines are typically complex and their poorly
characterised products have often raised safety concerns including
reversion to virulence for live attenuated pathogens, induction of
autoimmunity, or unacceptable reactogenicity associated with
the induced inflammatory response (Rappuoli et al., 2011).Additionally, critical conformational epitopes may be disrupted by
the inactivation process (Grimm and Ackerman, 2013). The most
infamous example of whole-organism virulence may be the ‘‘Cutter
Incident’’ in 1955 when thousands of American children were inad-
vertently immunised with live polio virus contained in what was
supposed to be an inactivated polio vaccine. This tragically resulted
in a number of deaths and many cases of paralysis (Brown, 1993),
and damaged the public’s perception of vaccine safety. Some of
these problems have been overcome with improved technology
and quality control, but even in recent years, unanticipated out-
comes have resulted from the use of whole-organism vaccines.
Recently, in Australia, an unexpectedly high number of adverse
events in children was associated with receipt of the 2010 trivalent
influenza vaccine (FluVax) manufactured by CSL Biotherapies (Aus-
tralia), possibly due to suboptimal virus splitting (Maraskovsky
et al., 2012). Even with the application of more advanced technolo-
gies to genetically attenuate the pathogen, the potential for the
pathogen to circumvent the attenuating mutation has been noted
(Mikolajczak et al., 2014). Moreover, increased public and regulatory
scrutiny of vaccine safety has raised the bar for what constitutes
acceptable risk for vaccines (Kennedy and Poland, 2011) and indeed
many, if not most, of the first generation whole-organism vaccines
that have proved successful and overwhelmingly safe (and saved
millions of lives) would not be approved for use today.
Additionally, the whole-organism approach is almost exclu-
sively restricted to pathogens that can be cultured in vitro, and
although it has worked for a number of ‘‘simple’’ pathogens with
relatively low antigen variability, it has not succeeded for many
complex pathogens including those that cause chronic infections
and are capable of evading or misdirecting the host immune
response. Also, traditional vaccine design is based on the premise
of mimicking the immunity induced by natural exposure, but for
many pathogens this is suboptimal and robust sustained protec-
tion may require inducing immunity that is better than nature,
with minimal adverse effects associated with stimulating the
inflammatory response (Zepp, 2010). This is especially true for a
chronic infection, where the pathogen is able to co-exist with the
host for an indefinite period of time despite the presence of
immune responses induced by the host and targeted against the
pathogen. Finally, for effective long-term protection, it is important
that the vaccine-induced immunity be sustained even in the
absence of pathogen exposure to allow for rapid recall of the
required immune memory.
To overcome these challenges, vaccine design has become more
tailored, focusing on the antigen moieties targeted by protective
immune responses (Zepp, 2010) with the conceptual framework
changing from a reductionist view to a holistic view, with a broad
perspective of the pathogen and its interaction with the host
immune system (D’Argenio and Wilson, 2010). Thus, the modern
era of vaccinology is multidisciplinary, exploiting enhanced knowl-
edge or improved understanding and technological innovations in
basic immunology, molecular biology, microbiology, host-pathogen
biology, microbial pathogenesis, genetics, biotechnology, bioinfor-
matics and computational science, as well as other fields
(D’Argenio andWilson, 2010; Kennedy and Poland, 2011). As noted
by Rino Rappuoli, ‘‘Vaccines have progressed from the crude
preparations used to prevent smallpox to one of the most techno-
logically advanced and effective public health interventions
devised by man’’ (Rappuoli et al., 2011).4. Rational vaccine development in the modern era
The ideal vaccine would induce robust and sustained immune
responses in all individuals in all populations, regardless of age
or immune status, in the absence of any adverse effects, and would
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gens (modified from Zepp, 2010). Rational vaccine design offers the
potential to achieve this goal, facilitated by advances in three core
areas: (1) conceptual advances, with improved understanding of
basic immunology, host-pathogen interactions and pathogenesis;
(2) technological innovations in molecular biology, biotechnology,
delivery systems and other enabling technologies; and (3) emerg-
ing knowledge in ‘omics’ and other data-intensive sciences, com-
bined with bioinformatics and computational biology capability
as well as cross-disciplinary approaches.
4.1. Conceptual advances
4.1.1. Learning from nature
Historically, vaccines have been designed to mimic the immu-
nity induced by natural exposure to the target pathogen (Zepp,
2010). In a number of cases, the phenotype of the critical respond-
ing cells, mechanisms of immunity and immunological memory,
and immune correlates of protection are unknown. As an example,
the BCG vaccine for tuberculosis developed in 1927 has been
administered approximately four billion times but its mechanism
of protective immunity is still not known (Kaufmann et al.,
2014). The premise of rational vaccine design is to induce the
desired immune response against the key pathogen antigen(s) or
epitopes which are targeted by protective immune responses. Dis-
secting the immune response to the target pathogen following nat-
ural infection in humans is a logical step to identify the immune
response(s) that should be induced by vaccination and the patho-
gen antigens targeted by that response(s). A number of factors
should be considered.
4.1.1.1. Immune activation – innate immunity, adaptive immunity,
and the innate/adaptive interface. The requisite steps leading to
in vivo immune activation have been reviewed in detail elsewhere
(Moser and Leo, 2010; Zepp, 2010; Six et al., 2012). Although tradi-
tional vaccine design has focused on the adaptive immune
response, it is now recognised that innate immune responses and
the innate-adaptive interface are critical for induction of robust
protective immune responses. The current state of knowledge indi-
cates that the rate limiting step for vaccination is antigen process-
ing and presentation by dendritic cells, which ultimately directs
the differentiation of functionally distinct subsets of immune cells
with different effector functions. Soluble proteins appear to be par-
ticularly poor in inducing dendritic cell maturation because, pre-
sumably, they lack the so-called ‘‘danger signal’’ but this
deficiency can be overcome at least in part by adjuvant formula-
tions (Moser and Leo, 2010). The choice of adjuvant has been dem-
onstrated to significantly impact vaccine efficacy (e.g. RTS,S
vaccine; (Stewart et al., 2006)). Nonetheless, until recently, Alum
was the only adjuvant globally approved for human use
(Eisenbarth et al., 2008), but MF59 and monophosphoryl lipid A-
containing formulations have received regulatory approval in
defined human vaccines (Rueckert and Guzman, 2012). Consider-
able efforts over the past few decades have been devoted to adju-
vant discovery, and some promising adjuvants are now moving
through the regulatory pipeline (Reed et al., 2013).
4.1.1.2. Activation of multiple arms of the immune system. Almost all
licensed vaccines currently available, as well as those that were
previously available but have been removed or replaced, rely on
the induction of functional antibodies which neutralise or opsonise
the target pathogen (Six et al., 2012; Delany et al., 2014). Some (e.g.
tetanus) work by neutralisation of the toxin. Although some of
these vaccines do induce cellular immune responses (e.g. pertussis,
(Mills et al., 1998); hepatitis B (Ren et al., 2003)), the protection is
thought to be antibody-mediated and, to the best of ourknowledge, there are no licensed vaccines that are specifically
designed to induce protective cellular immune responses. How-
ever, for many pathogens, including intracellular pathogens
(Seder and Hill, 2000), cellular immune responses play a critical
role in protection, either directly via CD8+ and CD4+ T cell cytotox-
icity targeting pathogen-infected cells or indirectly via cytokines or
other mediators produced by the T cells. Additionally, indirectly,
helper T cells are required for optimal B cell activation and high
affinity antibody responses, and influence the antibody isotype as
well as the development of immune memory (Moser and Leo,
2010; Zepp, 2010; Delany et al., 2014). Indeed, the development
of vaccines against those pathogens that have thus far proved elu-
sive will likely require activation of all arms of the immune system
with functional antibodies as well as efficient CD4+ and CD8+ T cell
responses, with appropriate selection of pathogen antigen relevant
for each immune response. Since conventional technologies have
proved ineffective in generating robust cell-mediated immunity,
innovative vaccine delivery systems will be crucial (see Section
4.2).
4.1.1.3. Quality of the immune response is not the same as quan-
tity. Conventional assessment of vaccine-induced immune
responses or correlates of immunity has typically focused only
on the frequency and magnitude, or quantity, of the immune
response; e.g. ELISA titres as a measure of the peak antibody
response; cytotoxic capacity or frequency of antigen-specific T
cells as a measure of the T cell response. However, the quality of
the immune response is at least as important as the quantity,
and quality can be a key determinant of protection (Zepp, 2010).
For example, the standard ELISA assay for antibody responses
quantifies antibodies that bind to the pathogen but this provides
no indication of the capacity of those antibodies to be functional
(Plotkin, 2008). In the case of antibody responses, quality can be
assessed via affinity, avidity, diversity and biological function, as
well as Ig subclass (Plotkin, 2008; Courtin et al., 2009; Feng
et al., 2009). For T cell responses, quality can be assessed via phe-
notypic markers, differentiation state (central memory, effector
memory, effector T cells), profile of secreted cytokines and poly-
functionality, TCR avidity and TCR repertoire diversity (Germain,
2010; Sallusto et al., 2010). For both antibodies and T cells, the gen-
eration and maintenance of immunological memory is critical to
ensure rapid reactivation upon pathogen exposure. Recent
advances in immune monitoring and immune profiling, and
establishment of consortia such as the Human Immunology Project
Consortium (http://www.immuneprofiling.org), provide the foun-
dation for comprehensive evaluation of vaccine-associated
immune parameters, and identification of novel immune
mediators and pathways (Newell et al., 2013; Poland et al., 2013;
Brusic et al., 2014).
4.1.1.4. Immune evasion, antigenic polymorphism and chronic dis-
eases. With the conceptual and technological advances of the past
decades, we have an improved understanding of antigenic poly-
morphism and immune evasion, and the associated challenges
for vaccine development, especially for chronic diseases. It is
now recognised that some pathogens are able to evade host immu-
nity by mutating key antigens or epitopes with evolutionary pres-
sure or during the course of disease. For example, the Plasmodium
spp. parasite has co-evolved with the human host over millions of
years with selection of polymorphisms within the human genome
that represent some of the most commonmonogenic human disor-
ders, such as a-thalassemia and hemoglobinopathies including
sickle-cell trait (Mackinnon and Marsh, 2010; Taylor et al., 2013).
Concomitantly, on the parasite side, polymorphisms within anti-
gens or epitopes targeted by host immune responses have been
demonstrated within relatively restricted time frames as a means
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Barry et al., 2009; Takala and Plowe, 2009). In addition to polymor-
phism at the nucleotide level, allelic polymorphism whereby more
than one allele exists for specific regions of a protein (e.g., Plasmo-
dium falciparum merozoite surface protein 1 or apical membrane
antigen 1; Plasmodium vivax Duffy Binding Protein), as well as anti-
genic variation of the asexual blood stages of Plasmodium where
the parasite expresses at any given time only one member of a
family of multi-copy variant surfaces antigens (e.g., PfEMP1), are
also well established (Takala and Plowe, 2009; Kirkman and
Deitsch, 2012). Examples of immune escape through antigenic
polymorphism or allelic variation have been also demonstrated
for other pathogens, with well known examples including influ-
enza (Yewdell, 2013), HIV (Moore et al., 2002; Boutwell et al.,
2010; Julien et al., 2012) and hepatitis C virus (Petrovic et al.,
2012). Such variation poses significant challenges for vaccine
development, since a vaccine that has high strain-specific efficacy
against the antigen included in the vaccine would nonetheless be
poorly effective against variant circulating strains in the field
(Moorthy and Kieny, 2010). This has been demonstrated experi-
mentally with a candidate three-component blood-stage vaccine
against malaria known as Combination B (Genton et al., 2002)
and subsequent field studies with recombinant merozoite surface
protein 1 (MSP1) (Ogutu et al., 2009; Otsyula et al., 2013) and api-
cal membrane antigen 1 (AMA1) vaccines (Ouattara et al., 2010,
2013; Thera et al., 2011). However, recent technological advances
(see below) have allowed the development of multivalent vaccines
against pathogens with multiple strains or serotype (e.g. the
licensed 7-valent, 10-valent or 13-valent conjugate vaccines for
Pneumococcus or the 4-valent vaccine for Meningococcus (De
Gregorio and Rappuoli, 2012). Other approaches have demon-
strated potential in preclinical evaluation, including chimeric vac-
cines (e.g. P. falciparum, Dutta et al., 2007; Faber et al., 2013)
mosaic vaccines (e.g. HIV, Corey and McElrath, 2010), or struc-
ture-based vaccine design (see Section 4.3.3).
4.1.1.5. Not all antigens are equal. It is now recognised that not all
antigens or pathogen-derived epitopes are equal in terms of their
capacity to be recognised by the host immune response. This phe-
nomenon, where pathogen-specific immune responses target only
a small fraction of the full range of possible antigens or peptide epi-
topes, is known as immunodominance (Sercarz et al., 1993; Allen
et al., 2001). The factors underlying the hierarchy of pathogen-
specific epitope recognition are largely unknown, especially in
the context of a complex pathogen, but could result from features
intrinsic to the protein antigen such as protein abundance, kinetics
of protein expression during infection, and rate of synthesis or
decay. It could also result from properties intrinsic to the
epitope(s), including efficiency of antigen processing and presenta-
tion, epitope abundance, major histocompatibility complex (MHC)
binding affinity or precursor frequency (Yewdell and Bennink,
2001; Assarsson et al., 2007; Kotturi et al., 2008; Tan et al.,
2011). The identification within this hierarchy of antigens (or epi-
topes) that are key targets of protective immune responses and
that will stimulate effective immunity against the target pathogen
is a key component of rational vaccine design (Rueckert and
Guzman, 2012). There is currently no algorithm or universal
approach to identify the important antigens and epitopes, and his-
torically antigens for inclusion in subunit vaccines have been
selected empirically, often based on antigen density and cell sur-
face accessibility. In some cases, cell surface proteins have proved
to be effective targets of neutralising antibodies; e.g. hepatitis B
surface antigen (Schillie and Murphy, 2013). However, in many
cases, antigens identified empirically may not be the optimal target
of protective immune responses, may be poorly immunogenic, or
may have associated safety concerns (Rappuoli et al., 2011).Advances in the genomic era, with the sequencing of pathogen
genomes and systems immunology approaches to define the requi-
site immune response, offer the potential to overcome these limi-
tations, particularly when the genome of the pathogen is large.
4.1.2. Improving on nature
As stated above, traditional vaccines aim to mimic the immu-
nity induced naturally following infection with the pathogen.
However, this approach has not been successful for many diseases,
including those caused by pathogens where immunity is typically
slow to induce and non-sterilising (e.g. malaria, RSV, Pseudomonas
aeruginosa) or where infections are chronic or have a latent phase
(e.g. HIV, hepatitis C virus, S. aureus) (Delany et al., 2014). Thus,
modern vaccinology must improve on nature. There are a number
of examples which demonstrate that this is possible, specifically:
(i) higher titres of neutralising antibodies can be induced in adults
by vaccination with a human papilloma virus virus-like particle
(VLP) vaccine adjuvanted with AS04 than are induced naturally
(Schwarz and Leo, 2008; Zepp, 2010). (ii) Human papilloma virus
VLP vaccines can induce a systemic protective immune response,
even though the virus enters only via the mucosal system and
remains localised to the basal cell layer of the squamous epithe-
lium (Schwarz and Leo, 2008; Zepp, 2010). (iii) Higher titres of
neutralising antibodies can be induced in children by vaccination
with Haemophilus influenzae type b, pneumococcal or meningococ-
cal polysaccharide-protein conjugate vaccines that convert the
induced antibody responses from T cell-independent to T cell-
dependent responses than are induced naturally (D’Argenio and
Wilson, 2010). (iv) A candidate vaccine against Chlamydia tracho-
matis infection comprising the major outer membrane protein
(nMOMP) solubilised with amphipols can induce more robust chla-
mydia-specific humoral and cell-mediated immune responses and
protective immunity in mice, by stabilising the protein and
increasing epitope accessibility (Tifrea et al., 2014). Additionally,
recent advances in approaches such as structural vaccinology are
specifically tailored to design vaccines that do better than nature
(see Section 4.3.3).
4.2. Technological innovations
Rational vaccine design in the modern era is facilitated by tech-
nological innovations in many areas including: (i) technical
advances in recombinant DNA technology and biotechnology; (ii)
manufacturing improvements including fermentation, production,
purification and consistency in manufacturing scale-up; and (iii)
enabling technologies which include novel vaccine platforms
(adjuvants, viral vectors, DNA vaccines, RNA vaccines, virus-like
particles (e.g. human papilloma virus vaccine, liposomes, nanopar-
ticles, mosaic vaccines)) as well as delivery systems (skin patches,
electroporation). These have been reviewed in detail elsewhere
(Hilleman, 1999; Zepp, 2010; Grimm and Ackerman, 2013).
4.3. Emerging knowledge from genome-scale datasets
Perhaps the most important influences on rational vaccine
design have been the tremendous advances made in the genomic
era, which began with the sequencing of the complete genome of
H. influenzae in 1995 (Fleischmann et al., 1995). Since then, the gen-
omes, proteomes and transcriptomes of many pathogens have been
elucidated (http://www.genomesonline.org/). This information
provides the foundation for novel 21st Century approaches to iden-
tify target antigens for the development of vaccines, drugs and diag-
nostic tests; for the development of innovative vaccine delivery
systems; and for the development and application of methods to
identify immune correlates of protection. These data-rich sets of
information have given rise to a large number of new scientific fields
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saries.com/content/omes.asp), as well as revolutionary conceptual
and technological advances which are largely cross-disciplinary.
Those most relevant to vaccine design include reverse vaccinology,
immunomics, structural vaccinology and systems immunology.
These, and others related to the field, have been reviewed elsewhere
by us (Doolan, 2011; Schussek et al., 2014) and others (Dormitzer
et al., 2008, 2012; Pulendran et al., 2010; De Gregorio and
Rappuoli, 2012; Grimm and Ackerman, 2013; Thomas and Luxon,
2013; Delany et al., 2014; Finco and Rappuoli, 2014), so will be only
briefly summarised here to provide context.
4.3.1. Reverse vaccinology
Reverse vaccinology, pioneered by Rappuoli and colleagues in
1999 (Rappuoli, 2000), is considered a milestone in vaccinology
and biotechnology because it exploits the power of in silico analy-
sis to identify, from the complete genome of the target pathogen, a
subset of genes encoding proteins with characteristics associated
with vaccine-induced immunity (e.g. location on cell surface)
which are then systematically evaluated for capacity to induce
the desired immune response/immunogenicity (Rappuoli, 2000).
Proof-of-concept for reverse vaccinology was established with
Neisseria meningitidis (Pizza et al., 2000), identifying in just
18 months more surface exposed antigens than had been discov-
ered in 40 years of conventional vaccinology; a vaccine based on
three of these novel antigens and outer membrane vesicles is
now licensed in 30 countries (Gorringe and Pajon, 2012).
4.3.2. Immunomics
Immunomics is the study of the subset of pathogen-derived
proteins or their epitopes that are recognised by the host immune
system. In contrast to reverse vaccinology, immunomics-based
identification of vaccine candidates relies not only on in silico pre-
diction algorithms, but also takes advantage of biological samples
from humans or animals with immunity to the disease of interest,
to define the set of antigens or epitopes that interface with the host
immune system (Doolan, 2011; Sette et al., 2005). Thus, immu-
nomics specifically addresses the interface between the host
immune system and the pathogen proteome (Klysik, 2001). No
vaccines derived from immunomics have yet reached the stage of
clinical testing but a number of promising candidate antigens have
been identified by us in the malaria model using antibody-based
(Doolan et al., 2008; Trieu et al., 2011) or T cell-based (Doolan
et al., 2003; Doolan, 2011) approaches.
4.3.3. Structure-based vaccine design or structural vaccinology
Most recently, advances in three-dimensional structural biology
enabling determination of protein tertiary structure and potential
conformational B cell epitopes has provided the foundation for
structural vaccinology or structure-based vaccine design
(Dormitzer et al., 2008, 2012; Thomas and Luxon, 2013; Delany
et al., 2014). The underlying rationale is that protective epitopes
(rather than complete proteins) should be sufficient to induce
immune responses and provide protection against pathogens,
and constructs can be engineered such that they are more stable,
expose hidden cryptic epitopes, or enable broadly cross-protective
responses against pathogen variants. Proof-of-concept has been
demonstrated in preclinical studies for a number of pathogens,
including the highly variant N. meningitidis serogroup B surface-
exposed factor H-binding protein, the group B Streptococcus pilus
protein, the F glycoprotein of RSV and influenza HA (Dormitzer
et al., 2012).
4.3.4. Systems immunology
Systems immunology (systems vaccinology) falls under the
broad umbrella of systems biology and aims to study the immunesystem in an integrated perspective rather than studying isolated
components, in order to identify immune correlates of protection
or signatures of immunogenicity (Querec et al., 2009; Pulendran
et al., 2010; Kaufmann et al., 2014). This approach, which success-
fully predicted the immunogenicity of the highly efficacious yellow
fever vaccine in humans (Querec et al., 2009), incorporates a holis-
tic view of the overall host-pathogen interaction as opposed to the
simple conventional readouts of vaccine-induced immune
responses such as ELISA or ELIspot assays (Six et al., 2012). Such
studies would be expected to provide a comprehensive under-
standing of the host-pathogen interaction and its regulation; to
identify novel immune mediators and pathways, and correlates
of vaccine efficacy, facilitating vaccine evaluation in the clinic.5. Malaria vaccine development
5.1. Challenges and feasibility
The Plasmodium parasite has a large, complex genome encoding
thousands of potential antigenic targets expressed at different
stages of a complex life cycle. It has developed a range of effective
strategies for evading the human immune response, including alle-
lic and antigenic variation, a predominantly intracellular existence,
and the ability to down-regulate the host’s immune response. Cur-
rent vaccine approaches have failed to yield an effective P. falcipa-
rum vaccine in spite of 50 years of dedicated effort. Nevertheless,
two experimental human vaccine models suggest that a malaria
vaccine is indeed a feasible goal.
Sterile infection-blocking immunity can be induced in mice,
monkeys and humans by immunisation with Plasmodium sporozo-
ites attenuated by radiation such that they can invade the host
hepatocyte but do not fully develop (Nussenzweig and
Nussenzweig, 1989; Hoffman et al., 2002). T cell responses (in par-
ticular CD8+ T cells) directed against parasite antigens expressed in
the infected hepatocyte are considered the primary immune effec-
tors, although antibodies also play a role in inhibiting sporozoite
invasion of the hepatocyte (Good and Doolan, 2010). Secondly,
individuals surviving past early childhood in areas of high malaria
transmission develop substantial clinical immunity and rarely die
from malaria, although they are frequently infected (Baird, 1998).
Antibodies directed against antigens exposed on the surfaces of
merozoites or infected erythrocytes, or released from apical organ-
elles at the moment of invasion, are thought to be the critical effec-
tors since passive transfer of purified immunoglobulin from
individuals with lifelong exposure to endemic malaria results in
a marked decrease in blood-stage parasitemia and resolution of
symptoms in the recipients (Cohen et al., 1961; Langhorne et al.,
2008). The human models represented by irradiated sporozoite
immunisation or naturally acquired immunity are powerful mod-
els for the development of a malaria vaccine to completely prevent
infection or death and severe disease, respectively.
More recently, a practical demonstration of the feasibility of a
malaria vaccine has been shown by the impact of the RTS,S vac-
cine. Although phase 3 results with RTS,S/ASO1 suggest that effi-
cacy is very low in the target age group and is not sustained
(Duncan and Hill, 2011; Olotu et al., 2013), the vaccine may none-
theless receive regulatory approval for implementation through
the routine Expanded Program for Immunisation (Bouchie,
2013) since modelling suggests that it may have an impact on
the number of ‘‘deaths averted’’ (Smith et al., 2012; Nunes
et al., 2013). These data are especially encouraging since the vac-
cine is based on only a single target antigen (P. falciparum cir-
cumsporozoite protein) amongst the more than 5,000 expressed
by the parasite. However these poor efficacy results highlight
the need to include more antigens and induce a broad multi-
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5.2. Progress, or lack thereof
Malaria vaccine development has focused on subunit vaccines
against a very limited number of target antigens (World Health
Organization, 2006; Schwartz et al., 2012). Nearly all Plasmodium
antigens present in the genome have the potential to be targets
for effective vaccines, drugs or diagnostic tests and remain so until
each is systematically assessed. What distinguishes one protein
from another for candidacy as a target for a new drug or as an
immunogen for a new vaccine is often determined empirically.
Selection of vaccine targets has been based on a variety of criteria
which, while not irrational, are not systematic. For example,
although some asexual blood-stage antigens were identified by
probing a cDNA expression library with antibodies present in
inhibitory sera from malaria-exposed individuals (Kemp et al.,
1983), other antigens have come to attention due to historical rea-
sons related to the ease with which murine or rabbit antisera were
generated against them. Their selection as candidate vaccine tar-
gets may be validated by immunoepidemiological evidence of
associations between immune responses and clinical immunity,
neutralisation or adoptive transfer experiments in animal systems,
or induction of protective immunity in animal models with homol-
ogous antigens from murine or simian malaria species.
For most of the past half century, malaria researchers attempt-
ing to develop a pre-erythrocytic stage malaria vaccine have
focused almost exclusively on a single antigen, the circumsporozo-
ite protein (CSP). Several lines of evidence supported the initial
focus on the CSP as a pre-erythrocytic stage vaccine candidate
(reviewed in Doolan and Martinez-Alier, 2006). In 1997, 16 years
after the CSP was identified and 15 years after GlaxoSmithKline
(UK) and the Walter Reed Army Institute of Research (WRAIR,
US) entered a collaborative agreement to produce a malaria vac-
cine, it was demonstrated that the RTS,S vaccine could protect
40% of malaria-naive volunteers against sporozoite challenge
(Stoute et al., 1997; Cohen et al., 2010). A review of the history
of the RTS,S vaccine is sobering since in the development effort
nearly a dozen other constructs based on the CSP were tested pre-
clinically and as many as six different vaccines were tested in the
clinic in Phase 1, Phase 1/2a challenge studies and up to Phase
2b studies in malaria endemic regions; some were efficacious but
the efficacy was marginal and significant research and develop-
ment (including almost 40 different clinical trials) was required
before the final vaccine candidate was identified (Cohen et al.,
2010). After 30 years of dedicated commitment from the pharma-
ceutical partner, GSK, phase 3 data are finally available which show
that the vaccine is far less efficacious in the target population than
anticipated and that the effect on clinical malaria is short-lived
(Olotu et al., 2013). Consistent with this, a number of studies have
established that although the CSP is the dominant sporozoite sur-
face protein, it is not a major component of the protective immune
responses induced by immunisation with radiation attenuated
Plasmodium sporozoites (Doolan et al., 2003; Gruner et al., 2007;
Kumar et al., 2006; Trieu et al., 2011).
In the case of erythrocytic stage vaccines, there has been a sim-
ilar, if slightly less restrictive, focus on a handful of candidate anti-
gen targets, particularly MSP1 (Fowkes et al., 2010) and AMA1
(Remarque et al., 2008), with a marked lack of success in the clinic
(Ogutu et al., 2009; Sagara et al., 2009).
There is reason to believe that such a narrow focus is inade-
quate and misplaced. A possible explanation for the unsatisfactory
efficacy of CSP-based vaccines, for example, comes from analysis of
immune responses in animals and human volunteers protected by
immunisation with irradiated sporozoites. While such volunteersdo generate antibody and T cell responses to CSP, they are often
very weak responses, substantially weaker than those induced by
immunisation with CSP itself (Doolan and Hoffman, 1997, 2000).
This discrepancy suggests that immune responses to CSP are not
a major component of the robust protection induced by immunisa-
tion with radiation-attenuated sporozoites, and is similar to the
low-level responses elicited in the volunteers to other candidate
pre-erythrocytic stage vaccine antigens, including SSP2/TRAP and
LSA1 (Doolan et al., 1997; Doolan and Hoffman, 2000). These find-
ings suggest two possibilities: either the protective immunity
induced by radiation attenuated sporozoites depends on a strong
response to a limited number of not-yet-identified antigens, or it
depends on the summation of a large number of weak responses
to many antigens. In either case, a focus on the large number of
other potential pre-erythrocytic stage vaccine candidates present
in the genome is warranted.
To date, few proteins in the Plasmodium spp. proteome have
been eliminated from consideration as potential vaccine candi-
dates, and many are being advanced as vaccine components in
clinical trials without rigorous evaluation of efficacy. Moreover,
subunit vaccines based on a single or few antigens may elicit a nar-
row breadth of response, providing neither optimal protection nor
protection on genetically diverse backgrounds. This protein-by-
protein approach has resulted in a long and largely unsuccessful
history of malaria vaccine development, with many candidate vac-
cine immunogens being in the development pipeline for decades
and many failures (World Health Organization, 2007; Schwartz
et al., 2012). It is likely that failure to develop a malaria vaccine
despite decades of effort can be attributed to this limited and arbi-
trary list of antigens, and that only by overcoming this restriction
will it be possible to identify vaccine targets suitable for inducing
protective humoral and cellular immune responses protecting
against chronic infections such as malaria. The requirement is both
to select optimally protective antigens and to ascertain whether a
few or many such antigens underlie the protective immunity
induced by immunisation with irradiated sporozoites (pre-eryth-
rocytic stage immunity) or by repeated exposure to infection
(blood-stage immunity). In our opinion, genome-based rational
vaccine design is the most logical, and only, way forward.
5.3. Whole parasite vaccine trend
The long and challenging history of malaria vaccine develop-
ment has caused a resurgence of interest in the whole-organism
approach established by Jenner in the 18th Century. This interest
builds on experimental evidence that whole parasite approaches
utilising either radiation-attenuated sporozoites or parasitised
red blood cells can protect in animal models of malaria, reviewed
extensively elsewhere (Butler et al., 2012; Epstein and Richie,
2013; Good, 2013; Good et al., 2013; Loukas and Good, 2013;
Vaughan and Kappe, 2013).
Briefly, the core approaches are: (i) metabolically active radia-
tion attenuated sporozoites being championed by Sanaria
(Hoffman et al., 2010; Seder et al., 2013); (ii) immunisation with
infectious P. falciparum sporozoites under chloroquine chemopro-
phylaxis (CPS) (Roestenberg et al., 2009, 2011; Bijker et al.,
2013); (iii) genetically attenuated liver stage and/or blood stage
parasites (Mueller et al., 2005; Spring et al., 2013; Mikolajczak
et al., 2014); and (iv) chemically attenuated blood stage parasites
(Good et al., 2013).
Although some promising results have been obtained in pre-
clinical models, it remains to be seen whether the many technical,
logistical and regulatory hurdles can be overcome (Menard, 2005;
Ballou and Cahill, 2007; Anders, 2011). In our opinion, the difficul-
ties associated with progressing whole-organism malaria vaccines
to the clinic are likely to be insurmountable and compel us towards
908 D.L. Doolan et al. / International Journal for Parasitology 44 (2014) 901–913a modern genome-based rational vaccine design, rather than a
return to the approach established over 200 years ago.
5.4. Genome-based rational vaccine design for malaria
Malaria represents an excellent model for genome-based vac-
cine design against complex pathogens because: (i) it is a signifi-
cant public health problem in the developing world; (ii) there are
two human models of protective immunity that establish the fea-
sibility of developing a malaria vaccine (immunisation by radia-
tion-attenuated Plasmodium sporozoites, relying on the
generation of protective cellular responses against pre-erythro-
cytic stage antigens; and naturally acquired immunity, relying on
the generation of protective antibody responses against blood
stage antigens); (iii) candidate antigens can be assessed either
in vitro (using an appropriate immune readout), in animal model
challenge systems (using the corresponding Plasmodium spp.), or
in humans by challenging with P. falciparum in a well-validated
human challenge model; (iv) both cellular and humoral immune
responses to several antigens simultaneously will be likely
required, in accordance with the two models of protection in
humans; (v) sub-optimal protection has already been achieved
using current molecular vaccine technologies, suggesting their fea-
sibility and potential for improvement; (vi) vaccines so generated
can be tested for safety and protection against sporozoite challenge
in the USA or Europe, and transitioned as appropriate to field test-
ing; and (vii) malaria, similar to many other important human
pathogens in the developing world, is a parasitic disease and thus
has developed mechanisms to avoid or modulate the host immune
system, meaning that the technological solutions developed for
malaria vaccine development should be translatable to other
chronic infectious agents.
5.4.1. Plasmodium ‘omics’
The complete genomic sequences of the human parasites P. fal-
ciparum (3D7 clone), P. vivax (Sal I strain), Plasmodium yoelii
(17XNL strain) and Plasmodium knowlesi (H strain) have been elu-
cidated (Gardner et al., 2002; Carlton et al., 2002; Pain et al., 2008).
Genome sequence data from nine Plasmodium strains are in various
stages of completion and are available to the research community
at PlasmoDB (http://www.plasmodb.org/) (Carlton et al., 2005,
2008; Aurrecoechea et al., 2009) together with partial genome
sequence for an additional 16 geographically diverse Plasmodium
parasites (15 P. falciparum, one Plasmodium reichenowi). With the
advent of next generation sequencing technology, the number of
completed and ongoing sequencing projects is rapidly increasing.
The sequencing of at least 105 geographically diverse Plasmodium
strains/isolates including 75 P. falciparum isolates, nine P. vivax iso-
lates, Plasmodium malaria and Plasmodium ovale, representative
simian malaria parasites (P. reichenowi, Plasmodium cynomolgi,
Plasmodium inui, Plasmodium coatneyi, Plasmodium fragile), rodent
parasites (Plasmodium chabaudi, P. yoelii, and Plasmodium berghei),
an avian parasite (Plasmodium relictum), and a reptile parasite
(Plasmodium mexicanum) is in progress (Cai et al., 2012).
In addition to this genomic data, high throughput transcripto-
mics and proteomics technologies, including microarray DNA chip,
mass-spectrometry, yeast two-hybrid (Y2H) screening and most
recently RNA-seq, NSR-seq and CHIP-seq, have been used to char-
acterise and profile the expression, regulation and interaction of
Plasmodium genes at the level of the transcriptome, proteome,
metabolome and interactome (Winzeler, 2006; Cai et al., 2012).
Large-scale proteomic datasets are also available for several life
cycle stages (P. falciparum, P. berghei and P. yoelii) (Florens et al.,
2002, 2004; Hall et al., 2005; Khan et al., 2005; Tarun et al.,
2008). Transcriptomic data are now available from multiple life-
cycle stages or gene knock-out mutants of P. falciparum and P. berg-hei (Hall et al., 2005) as well as multiple stages of P. yoelii (mos-
quito, erythrocytic and liver stages) (Tarun et al., 2008;
Mikolajczak et al., 2008; Zhou et al., 2008; Lasonder et al., 2008),
P. vivax isolates (Bozdech et al., 2008) and other P. falciparum
strains (Rovira-Graells et al., 2012). Other datasets include
expressed sequence tag (EST) data from over 130 libraries (P. falci-
parum, P. vivax, P. berghei and P. yoelii) (Watanabe et al., 2007;
Tarun et al., 2008; Florent et al., 2009) and serial analysis of gene
expression (SAGE) data (P. falciparum only) (Patankar et al., 2001;
Gunasekera et al., 2003, 2004). Most recently, transcriptome anal-
ysis by next generation sequencing (RNA-seq) has provided infor-
mation about the abundance of all transcripts in the
transcriptome by considering the real number and the level of dif-
ferent transcript isoforms (Otto et al., 2010; Lopez-Berragan et al.,
2011; Lindner et al., 2013). Moreover the combination of transcri-
ptomics analysis with ChIP-seq data has provided new insights to
unravel the regulation of gene expression (Lopez-Barragan et al.,
2011; Hoeijmakers et al., 2012). Other studies have provided trans-
criptomics data on clinical isolates using NSR-seq (Vignali et al.,
2011). Expression profiling data throughout the intraerythrocytic
cycle (oligonucleotide-based microarrays in both glass slide and
Affymetrix formats) as well as single nucleotide polymorphism
(SNP) analysis for 20 P. falciparum strains and 100 P. falciparum iso-
lates (Jeffares et al., 2007; Mu et al., 2007; Volkman et al., 2007) are
also available. Additional functional data sets include evidence of
protein–protein interactions (Y2H and predicted interactome)
(LaCount et al., 2005; Date and Stoeckert, 2006); Genome Ontology
(GO) (Ashburner et al., 2000) and InterPro domain (Mulder et al.,
2005) annotations for P. falciparum, P. vivax, P. berghei, P. yoelii, P.
knowlesi and P. chabaudi; Enzyme Commission (EC) number
(Ashburner et al., 2000) annotations for P. falciparum, P. yoelii and
P. knowlesi (Ginsburg, 2006); and metabolic pathway assignments
for P. falciparum (Ginsburg, 2006). Predictions of protein subcellu-
lar localisation (Bendtsen et al., 2004) and transmembrane
domains (Krogh et al., 2001) for P. falciparum, P. vivax, P. berghei,
P. yoelii, P. knowlesi and P. chabaudi are available, as well as para-
site-specific predictions (P. falciparum only) for apicoplast localisa-
tion (Foth et al., 2003) and for export to the host cell (Hiller et al.,
2004; Marti et al., 2004, 2005).
These analyses of genomics, proteomics, transcriptomics, inter-
actomics and, most recently, next generation sequencing, allow for
investigation at the molecular level of drug resistance, immune
evasion and pathogenesis, and provide the foundation for antigen
discovery and prioritisation on a genome-wide or proteome-wide
scale. Web-based databases such as PlasmoDB (http://plas-
modb.org/) and GeneDB (http://www.genedb.org/) providing pub-
lic access to the data and advanced statistical and bioinformatics
algorithms and analytical tools such as BioGRID (http://thebio-
grid.org/), Pathway Commons (http://www.pathwaycom-
mons.org/) and STRING (http://string-db.org/), allow the
researcher to visualise, analyse, integrate and interrogate the data.
Overall, these datasets provide a comprehensive foundation for
genome-based vaccine design.
5.4.2. Applied ‘omics’
With this wealth of genomic, proteomic, transcriptomic and
related data, the tools to exploit these data, and biological samples
from human volunteers, we have an unprecedented opportunity to
develop and implement a rational approach to target antigen selec-
tion and vaccine design. In our view, the ‘‘post-genomics’’ era of
vaccine research should focus on leveraging these genome-scale
datasets for objective evidence-based assessment of candidate tar-
gets for rational vaccine development. Rational and systematic
genome-based strategies overcome the deficiencies of the current
ad hoc approach to target selection. Importantly, they take advan-
tage of the two human models of immunity which depend on
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thousands of potential immune targets, while aiming to ‘‘improve
on nature’’.
Already, exploitation of genomic data with systematic
approaches to rational drug design and target selection (chemoge-
nomics) has led to the identification of new classes of antimicrobial
drugs (Bhattacharjee et al., 2013). Progress towards genome-based
vaccine design is well under way and showing great potential. In
our laboratory, we are using the power of immunomics to address
two situations: one (predominantly pre-erythrocytic, based on the
irradiated sporozoite model) in which T cell targets are selected,
and one (predominantly erythrocytic, based on naturally acquired
immunity) in which antibody targets are selected. We are using
biological specimens (T cells and plasma/sera) from individuals
immunised with irradiated sporozoites or naturally exposed to
malaria, or immunoglobulin from clinically immune individuals,
for in vitro immune screening to assess the capacity of the antigen
to be recognised by recall of Plasmodium-specific immune
responses in protective human models using clinically relevant
selection criteria. We have generated unique ‘omic’-scale datasets
of proteome-wide T cell responses and antibody responses to Plas-
modium by systematically screening the Plasmodium proteome
using protein microarrays and epitope prediction algorithms, with
specimens from humans, non-human primates or rodents natu-
rally or experimentally exposed to malaria. (Doolan et al., 2008;
Crompton et al., 2010; Barry et al., 2011). Analysis of these compre-
hensive datasets has revealed that the target antigens of antibody
or T cell responses are not randomly distributed throughout the
proteome, and that only approximately 30% of the proteome is
recognised. We have also established that a large number of newly
identified antigens are more immunogenic than antigens identified
by traditional methods. Furthermore, antigens that are highly reac-
tive for T cells are not serodominant for antibody responses (Doo-
lan, D.L., unpublished data), suggesting that different approaches
are required to identify the most effective targets of T cell and anti-
body responses. These data establish proof-of-concept for both T
cell- and antibody-based approaches to identify antigens and epi-
topes which represent promising candidates for next generation
malaria vaccine development. They also support the premise that
omics-scale approaches offer promising solutions to the challenge
of vaccine development for complex pathogens.6. Conclusion
There is currently no accepted rational approach to vaccine
design and target selection for malaria or any other complex path-
ogen. We advocate a rational approach to malaria vaccine design
capable of exploiting the wealth of genomic, proteomic and bioin-
formatic information that has been developed in the genomic and
post-genomic eras. We believe that rational genome-based vaccine
design, enabling the selection of the best possible targets by prior-
itising antigens according to clinically relevant criteria (frequency
and magnitude of clinically relevant immune response and/or bio-
logical function), will overcome the problem of poorly immuno-
genic, poorly protective vaccines that has plagued malaria
vaccine developers for the past 25 years. Clearly, additional work
will be required to bring rationally-designed vaccines to the clinic,
including pre-clinical safety testing, optimisation of immunogenic-
ity, phased human clinical trials, and large scale production and
distribution. However, appropriate approaches and standard pro-
tocols for these steps are well-established and these remaining
steps are not part of the critical roadblock to malaria vaccine devel-
opment. There remain economic roadblocks to production and
licensing of an effective vaccine even after efficacy and safety are
demonstrated. We believe, however, that once an effective malariavaccine has been developed, private and governmental sources will
be persuaded to provide adequate resources to support production
and distribution and, once distributed, the vaccine is likely to meet
with wide acceptance in Africa. Extension of this approach to other
pathogens will require a substantial research investment, however
such effort will undoubtedly be worthwhile.
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